IDEAYA Biosciences, Inc. (IDYA)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 16
in 89 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
IDEAYA Biosciences’ EPS trailed consensus in the third fiscal quarter of 2026, with EPS of -$1.22 coming in below the -$1.18 estimate by -$0.04, as the company posted sharply lower revenue; the results were reported on November 3, 2026. Revenue fell 95% to about $10.2 million, down from roughly $207.8 million a year ago, as the quarter reflected a much smaller top line versus the prior-year period. Profitability remained negative, with operating income of about -$137.6 million alongside a net loss of roughly -$125.7 million, compared with net income of about $119.2 million a year ago, and the reported EPS compared with $1.33 in the year-ago quarter. For the next period, consensus calls for EPS of -$1.13 on revenue of $18.6 million.
About IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is a biotechnology company focused on precision oncology, developing targeted cancer medicines for molecularly defined patient groups. In FY2025, it generated $218.7 million in revenue. The company centers its approach on synthetic lethality, using genetic and molecular diagnostic selection to match therapies to specific tumor vulnerabilities.
Today's Snapshot
IDYA closed 3.3% lower on heavier trading than usual. IDEAYA Biosciences outlined an FDA-backed late-stage trial plan for IDE849, an experimental cancer drug.
Trading Volume
Above 10d avg 1.1M
1.4M
vs S&P 500 Today
Strong Underperformance
-3.06%
Updated: November 18, 2026 at 21:11 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$30.14 - $34.61Sell
- RSI (14)27.09Buy
- Stochastic %K (14, 3, 3)6.40Buy
- MACD Level (12, 26)-1.71Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.